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ABSTRACT 
 
Background and aims: Diabetes mellitus (DM) is one of the most common contributors of chronic kidney 
disease (CKD). The epidemiology of CKD, a concern among patients with DM, has not been studied in 
Botswana. The aim of this study was to estimate its prevalence among these patients to provide future 
guidance to both government personnel and physicians. Methods: Observational cross-sectional study in 
a leading clinic in Botswana. Demographic and clinical data were obtained from patients through 
interviews and from their notes using a standard questionnaire. The study was conducted from July to 
October 2015. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of 
Diet for Renal Disease equation. CKD was defined as an eGFR < 60 ml/min/1.73m2. Multivariable logistic 
regression analyses were performed to assess the associations between CKD and potential factors. 
Results: Mean age and duration of diabetes mellitus among study participants were of 54.67 years (range 
21-92 years) and 5.0 years respectively. Over half, i.e. 213/370 (57.6%) and 232/370 (62.7%), had an 
average blood pressure greater than 140/90mmHg and poor glycemic control (HbA1c >7%) respectively. 
31/370 patients (8.4%) had CKD. However, only 18/370 (4.9%) had a diagnosis of CKD documented in 
their charts. Age, level of education, and duration of diabetes were independently associated with CKD.  
Conclusion: The prevalence of CKD by estimated eGFR was low compared to most previous studies. 
However, half of patients with CKD are not documented resulting in potential prescription errors and drug 
toxicity. A substantial number of patients had uncontrolled hypertension and poor glycemic control. Older 
age, low level of education and longer duration of DM were associated with CKD. There is a need to carry 
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out prospective studies to determine the association and role of glycemic and blood pressure control in 
CKD causation among patients with DM in Botswana. 
 
1. INTRODUCTION 
 
Diabetes mellitus (DM) is of major public health importance as it poses a considerable threat with its 
growing prevalence and implications on morbidity, mortality, and costs, due to both microvascular and 
macrovascular complications if not adequately addressed [1-5].  DM also appreciably impacts on the 
quality of life of patients [6-8]. Approximately 415 million people worldwide had DM in 2015, with the 
number expected to appreciably increase to approximately 640 million by 2040 [9,10]. There is currently a 
global disproportionate burden of DM, with the highest rates now found in Africa and Asia [10]. Sub-
Saharan Africa presents a higher rate of DM burden with the number of people with diabetes expected to 
increase by more than 161% from 8 million in 2000 to 18 million by 2030 [10], with others suggesting the 
prevalence of diabetes in Africa is already 16 million [11].  
 
Complications of DM appear more prevalent in Africa compared to developed countries due to a myriad 
of factors. These include late presentation, poor glycemic control, lack of diagnostics to screen for 
complications at early stages, and failure to treat complications at early stages [3, 12].  
 
Chronic kidney disease (CKD) is one of the complications of diabetes [13].  Progression of CKD with 
lower estimated glomerular filtration rates also leads to constraints in the overall management of DM with 
oral hypoglycemic agents (OHA). Optimal glycemic control is not easy to achieve due to limited options of 
suitable OHAs in CKD patients outside of newer therapies such as the dipeptidyl peptidase-4 (DPP-4) 
inhibitors [14,15]; consequently, the tendency is to prescribe insulin as CKD progresses towards end-
stage renal disease (ESRD) [16, 17].  Despite the fact that insulin is metabolized by the kidney, with a 
resulting decline in renal function being a risk for hypoglycemia, it is still safe to use insulin in Type 2 DM 
patients as titration to lower doses is possible unlike the use of oral hypoglycemic agents, which are 
usually only available in fixed dose combinations.  
 
CKD is increasingly becoming a global epidemic. According to World Health Organization (WHO), there 
were approximately 220 million people globally with CKD in 2012 [18]; the majority of which are attributed 
to DM followed by hypertension [18-20]. DM and kidney disease are independent risk factors for 
cardiovascular events. When the two occur together, the risk for cardiovascular morbidity and mortality is 
increased by more than if these events were to occur separately [16, 18]. In a study undertaken in the 
USA, there was an increase of 19-40% of cardiovascular events as glomerular filtration rate declined from 
normal ranges to below 45m L/min/1.73m2 [21].  
 
According to the 2012 Kidney Diseases Improving Global Outcomes (KDIGO) guidelines, CKD is defined 
as abnormalities of kidney structure or function that persist for over three months. In the same regard, 
abnormal function is defined as estimated GFR < 60 ml/min/1.73m2, whereas markers of kidney damage 
include albuminuria, renal tubular disorders, abnormal urinary sediments, biopsy findings, and structural 
abnormalities on imaging [22]. Early diagnosis of CKD is of paramount importance due to the fact that 
appropriate management can be instituted to prevent deterioration to ESRD, which requires renal 
replacement therapy which is very expensive [23-26] and ultimately associated with poor quality of life. 
CKD itself is also associated with reduced health-related quality of life [27,28]. 
 
Previous studies have linked several sociodemographic and clinical variables to the occurrence of CKD in 
DM. Specifically factors that have consistently been associated with higher rates of CKD include older 
age, male sex, African-American ethnicity, obesity, family history of CKD, diabetes mellitus and 
hypertension [29, 30].  Despite the high burden of DM and its complications in Africa, there is currently 
limited literature on the complications of DM including CKD in this continent. Consequently, this study was 
conducted to determine the prevalence of CKD using estimated glomerular filtration rate (e GFR) in a 
leading clinic setting in Botswana, as well as elicit possible factors associated with CKD, to provide future 
guidance not only to better manage DM patients in Botswana to reduce CKD but also potentially wider. 
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2. MATERIALS AND METHODS 
 
2.1 Study design, setting, population:  
This was a descriptive observational cross-sectional study undertaken in a tertiary clinic in Gaborone, the 
capital city of Botswana. However, this clinic also operates as a primary care centre because almost all 
the patients with DM in Gaborone are treated at this clinic. Consequently, the clinic can provide a 
representational sample of the DM patients within Botswana.  
 
A cohort of 380 patients was randomly selected and interviewed between July 2015 and September 
2015. Clinical and laboratory data were obtained from patients’ charts and Integrated Patients 
Management system (IPMS). Details of the study design including the number of patients enrolled, the 
setting, population and a description of the sociodemographic and clinical characteristics of these patients 
have been described in previous publications [6, 8,].  For the purpose of this study, the most recent 
laboratory results of serum creatinine that was within six (6) months of patients’ recruitment was recorded 
for the purpose of calculating patients’ renal function in the form of estimated glomerular filtration rate (e 
GFR).  
 
The study was approved by Ethical Review Boards of University of Botswana, Princess Marina Hospital 
and Ministry of Health Botswana. 
 
2.2 Data collection 
From the cohort of 380 patients recruited in the primary study [8], 10 patients were excluded as they had 
missing serum creatinine in IPMS; consequently, 370 patients were included in the final analysis. In 2015, 
serum creatinine was measured using Beckman Coulter AU680 clinical chemistry machine (CA, United 
States) calibrated by modified Jaffe method. Frequency of calibration is daily and is accomplished by the 
use of chemistry calibrator (Cat $# DR0070), which is traceable to an isotope dilution mass spectrometry 
(IDMS) reference method using the National Institutes of Standards and Technology (NIST) Standard 
Reference Material 967 [31]. 
 
Using serum creatinine levels, the estimated glomerular filtration rate for each patient was computed 
according to the equation of modification of diet in renal disease (MDRD): eGFR = 186 × (serum 
creatinine × 0.0113)–1.154 × (age)–0.203 × (0.742 if female) [32], where eGFR is measured in ml/min per 
1.73m2, creatinine is in μmol/L, and age in years. Patients were then categorized to have CKD if eGFR 
was < 60 ml/min per 1.73m2 and not to have CKD if eGFR was ≥ 60 ml/min per 1.73m2 [22]. MDRD 
equation has not been validated for use in Botswana, however it was chosen because it is recommended 
by National Kidney Foundation [33]; as well its use in this study provides room for comparisons with other 
studies that used similar equation [34-36] 
 
2.3 Measurements 
The processes and criteria used to select and categorize different sociodemographic and clinical 
variables used in this this study has been described in detail previously [6, 8].  We chose the following 
variables to determine the association with CKD: age, gender, level of education, marital status, body 
mass index, type of DM, duration of diabetes, modality of treatment for DM, glycemic control, blood 
pressure control and HIV status. HIV status is important in sub-Saharan countries such as Botswana 
given its high prevalence rate as well as high prevalence of patients with both HIV and DM [6]. 
Consequently, potentially a very different population to Western countries. 
 
2.3 Data analysis 
The analysis was performed by SPSS version 22 statistical software.  We obtained proportions for the 
study participants’ sociodemographic and clinical characteristics and CKD – related status. Subsequently, 
we computed factors associated with CKD in previous studies using unadjusted logistic regression, with 
significant factors run in a separate multivariable adjusted regression to determine their independent 
association to CKD. A p-value of less than 0.05 was considered statistically significant. 
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3. RESULTS 
 
3.1 Sociodemographic and Clinical characteristics 
Baseline sociodemographic and clinical characteristics of studied patients have been described in detail 
elsewhere [6,8]. Of importance to this study as regards to patients’ characteristics is that the mean age of 
study participants was 56.47 years. Close to half of them had been diagnosed less than 5 years prior to 
recruitment, with a mean duration of diabetes of 5 years. 60.1% had poor glycemic control and 57.4% had 
uncontrolled hypertension [6,8].  On the other hand, 18/370 (4.9%) of our patients had documented 
evidence of kidney disease in their charts. 
 
3.2 CKD prevalence 
Among the study population, 31/370 (8.4%) had CKD categorized as eGFR < 60 mL/min/1.73m2. Of note 
is the fact that, eGFR of > 90, 60-89, 30-59 (CKD stage 3) and 15-29 (CKD stage 4) mL/min/1.73m2 
accounted for 74.1%, 17.6%, 7.0% and 1.4% respectively. There was no recruited patient with end-stage 
renal disease (Table 1). 
 
Table 1: Prevalence of chronic kidney disease among study participants 
 
CKD status Number (n) Percent (%) 
GFR < 60 
GFR ≥ 60 
Total 
31  
339  
370  
8.4 
91.6 
100 
GFR ≥ 90 
GFR 60-89 
GFR 30-59 
GFR 15-29 
Total 
274 
65 
26 
5 
370 
74.1 
17.6 
7.0 
1.4 
100 
 
3.3 Pattern of antidiabetic medication by stage of CKD 
Metformin and glibenclamide were the most commonly prescribed oral hypoglycemic agents (OHAs) used 
by 309/370 (83.6%) of all patients, with only 4 patients using pioglitazone in addition to common OHAs. 
Use of insulin alone accounted for 51/370 of all patients. There was a high likelihood of patients being on 
insulin alone in CKD stage 4 (80%) compared to CKD 3 (26.9%) and estimated GFR of 60-89 and ≥ 90 
where insulin alone was used by 7.7% and 12.8% respectively. This association was statistically 
significant (p value = 0.000) (Table 2).  
 
Table 2: Pattern of antidiabetic medication prescription by stage of CKD 
 
 Modality of diabetes mellitus treatment 
CKD status Diet Oral 
hypoglycemic 
agent (OHA) 
Insulin Both OHA 
and Insulin 
Total p-value 
GFR ≥ 90 
GFR 60-89 
GFR 30-59 
(Stage 3) 
GFR 15-29 
(Stage 4) 
Total 
2 
1 
1 
 
0 
 
4 
174 
37 
5 
 
1 
 
217 
35 
5 
7 
 
4 
 
51 
63 
22 
13 
 
0 
 
98 
274 
65 
26 
 
5 
 
370 
 
 
<0.0001 
 
Using the study definition of CKD, the association was also found to be statistically significant with either 
OHAs or OHAs/Insulin more likely to be used in patients without CKD (p value = 0.001) (Table 3). 
 
5 
 
Table 3: Association between sociodemographic and clinical characteristics to CKD 
 
Variables Without CKD 
(GFR ≥ 60) n 
(%) 
With CKD 
(GFR<60)  
n(%) 
Crude OR (95% CI) p-value 
Age 
21-35 
36-50 
51-65 
>65 
 
30 (100%) 
75 (97.4%) 
152 (93.8%) 
82 (81.2%) 
 
0 (0%) 
2 (2.6%) 
10 (6.2%) 
19 (18.8%) 
0.297 (0.164-0.540) < 0.0001 
Gender 
Male 
Female 
 
103 (92.8%) 
236 (91.1%) 
 
8 (7.2%) 
23 (8.9%) 
0.797 (0.345-1.841) 0.595 
Level of 
education 
No formal 
education 
Less than primary 
Primary school 
completed 
Secondary school 
completed 
 College/ 
University 
Postgraduate 
completed 
 
 
57 (82.6%) 
 
70 (90.9%) 
94 (92.2%) 
 
74 (98.7%) 
 
 
38 (92.7%) 
 
6 (100%) 
 
 
12 (17.4%) 
 
7 (9.1%) 
8 (7.8%) 
 
1 (1.3%) 
 
 
3 (7.3%) 
 
0 (0%) 
1.584 (1.157-2.172) 0.003 
Marital status 
Never married 
Currently married 
Separated 
Divorced 
Widowed  
Cohabiting 
 
93 (94.9%) 
138 (90.2%) 
2 (100%) 
13 (100%) 
65 (86.7%) 
28 (96.6%) 
 
5 (5.1%) 
15 (9.8%) 
0 (0%) 
0 (0%) 
10 (13.3%) 
1 (3.4%) 
0.930 (0.753-1.144) 0.493 
Body Mass Index 
(BMI) 
Underweight 
Normal weight 
Overweight 
Obese 
 
 
5 (100%) 
57 (87.7%) 
89 (94.7%) 
148 (90.2%) 
 
 
0 (0%) 
8 (12.3%) 
5 (5.3%) 
16 (9.8%) 
0.993 (0.626-1.575) 0.975 
Type of Diabetes 
Type 1 
Type 2 
 
22 (95.7%) 
317 (91.4%) 
 
1 (4.3%) 
30 (8.6%) 
0.480 (0.063-3.689) 0.481 
Duration of 
Diabetes (years) 
<5 
5-10 
>10 
 
 
168 (96.0%) 
77 (90.6%) 
80 (86.0%) 
 
 
7 (4.0%) 
8 (9.4%) 
13 (14.0%) 
0.514 (0.324-0.816) 0.005 
Modality of 
treatment 
Diet 
Oral hypoglycemic 
agents (OHA) 
Insulin 
Both OHA and 
Insulin 
 
 
3 (75.0%) 
211 (97.2%) 
 
40 (78.4%) 
85 (86.7%) 
 
 
1 (25.0%) 
6 (2.8%) 
 
11 (21.6%) 
13 (13.3%) 
0.516 (0.345-0.772) 0.001 
6 
 
Glycemic control 
Good 
Poor 
 
106 (92.2%) 
213 (91.8%) 
 
9 (7.8%) 
19 (8.2%) 
0.952 (0.416-2.175) 0.907 
Blood Pressure 
Controlled (< 
140/90 mmHg) 
Uncontrolled ≥ 
140/90mmHg) 
 
149 (94.9%) 
 
190 (89.2%) 
 
8 (5.1%) 
 
23 (10.8%) 
0.444 (0.193-1.020) 0.056 
HIV status 
Positive 
Negative 
Unknown 
 
36 (94.7%) 
210 (92.5%) 
93 (88.6%) 
 
2 (5.3%) 
17 (7.5%) 
12 (11.4%) 
0.642 (0.341-1.206) 0.168 
 
3.4 Factors associated with CKD 
 
Older age (OR=0.297, p=0.000), lower levels of education (OR=1.584, p=0.003), and a longer duration of 
diabetes (OR=0.516, p=0.001) were associated with CKD in bivariate analysis. The remaining studied 
factors including gender, marital status, body mass index, type of DM, glycemic control and HIV status 
were not associated with CKD (Table 3). The relationship between CKD and glycemic control was not 
significant even when CKD stages 3 and 4 were analyzed separately (p=0.963) (Table 4).  
 
Table 4: Glycemic control of study participants by CKD stages 
 
                     Glycemic control p-value 
CKD stages Good control Poor control Total 
GFR ≥ 90 
GFR 60-89 
GFR 30-59 (Stage 
3) 
GFR 15-29 (Stage 
4) 
Total 
84 
22 
7 
 
2 
 
115 
172 
41 
16 
 
3 
 
232 
256 
63 
23 
 
5 
 
347 
 
 
 
0.963 
 
The significant variables in the bivariate analysis were subsequently subjected to a separate multivariable 
logistic regression model, whereby all three variables (age, education level and duration of diabetes) 
remained statistically significant (Table 5). 
 
Table 5: Multivariate logistic regression for factors associated with CKD 
 
Variable AOR Rat 95% CI P value 
Age 3.52 1.565 – 7.928 0.002 
Level of education 3.60 1.23-10.55 0.02 
Duration of diabetes 3.90 1.498 – 10.15 0.005 
 
4. DISCUSSION 
 
We found the prevalence of CKD to be 8.4% as defined by an estimated glomerular filtration rate (eGFR) 
<60 ml/ min/1.73 m2. These findings are almost similar to those observed elsewhere in primary care 
settings [37, 38], with our tertiary clinic typically operating as a primary care clinic for DM patients in 
Gaborone. On the other hand, the prevalence of CKD in this study appeared low compared to most other 
studies, which revealed a prevalence based on estimated glomerular filtration rate of (eGFR) <60 ml/ 
min/1.73 m2 in the range of 18-24.7% [34,35,39,40]. The low prevalence in this study may well partly be 
attributed to the fact that we included type 1 DM patients in our analysis. Type 1 DM patients have a 
natural history of developing CKD after many years following diagnosis, whilst patients with type 2 DM are 
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likely to present with complications after only a few years due to late diagnosis. The other possibility is 
that our patients were mostly diagnosed less than 5 years prior to entering this study; the lower 
prevalence may be according to the natural history of the disease. The contribution of genetics to the 
prevalence of CKD among DM patients in terms of contributing to the rate of renal impairment in 
Botswana is unknown and this may require further research in the future. 
 
The importance of strict glycemic control (HbA1c < 7%) and blood pressure control in preventing and 
slowing the progression of CKD has been well documented [41-44].  Our study revealed that 60.1% and 
57.4% of study participants had poor glycemic control and uncontrolled blood pressure respectively. This 
is concern since if situation is not adequately addressed; there is a high likelihood of an increasing 
incidence of CKD in these patients. Consequently, we now recommend strict glycemic control and a more 
aggressive approach to controlling hypertension in this population, and we will be following this up in 
future research.  
 
Glycemic control was not associated with the stages of CKD in our study. There was overall poor 
glycemic control across all stages, which can be interpreted that even patients with estimated GFR > 60 
ml/min/ 1.73m2 are at increased risk of CKD. Previous studies have shown that as CKD patients progress 
to end stage kidney disease (ESRD), their glycemic control tends to significantly improve due to factors 
such as HbA1c underestimating their control as well as associated loss of weight/poor appetite and more 
access to care leading to stressing the importance of glycemic control [45]. We did not recruit patients 
with ESRD in our study since most patients who are on dialysis attend the nephrology clinic in Botswana 
where they also receive care for their DM. We can speculate that most of them had better glycemic 
control; consequently, reducing the need for attending multiple clinics.  
 
Blood pressure control is a key component of preventing and slowing progression of CKD; consequently, 
most guidelines emphasize the importance of reaching therapeutic goals such as < 140/80 mmHg [46, 
47].  Despite the fact that we used a less strict goal of < 140/90 mmHg during our analysis, the majority of 
our patients still had uncontrolled blood pressure. We did not find any significant association between the 
level of blood pressure control and CKD. This is in contrast to other studies which showed CKD to be 
more associated with uncontrolled hypertension [34,39].  One possible explanation is the higher numbers 
of uncontrolled blood pressure among both patients with and without CKD in our study. The other reason 
could be that our study was not powered enough to show the effect of blood pressure on CKD. 
 
Several sociodemographic factors and clinical variables were analyzed in our study to find any 
association with CKD. While there have been contradictory findings on the effect of gender on CKD, it has 
been shown in some studies that women tend to have a higher rate of severe kidney injury with 
albuminuria compared to men [48]. The other explanation being that male patients tend to be associated 
with a higher rate of CKD with higher mortality, whilst women have a survival benefit and appear to have 
higher CKD prevalence rates [48, 49].  Other studies though have shown that males tend to have a higher 
prevalence of CKD compared to women [50, 51].  In our study, there was no association between gender 
and the presence of CKD, which is similar to findings in other previous studies [40, 49, 52].  
 
Chronic kidney disease was found to be significantly associated with older age. This is expected due to 
the fact that people tend to lose glomeruli with aging, and an association of age with CKD has been 
documented in several studies [34, 40, 53].  On the other hand, it has been established that CKD 
prevalence is associated with longer duration of DM [34, 54, 55]. Similarly, we found a significant 
association between CKD and the duration of DM. 
 
On the other hand, we found that higher level of education was associated with less prevalence of CKD. 
This is in contrast to other previous studies that have shown education is not associated with CKD [40, 
56].  Our results could possibly be explained by difference in other lifestyle factors such as dietary intake, 
smoking and alcohol use which were not assessed in this study. We are also aware that issues such as 
educational status and knowledge about the disease can impact on medicine adherence rates in practice 
in patients with chronic diseases in Africa; although this is not universal [6, 57-60]. Consequently, there is 
a need for further research to explore the contribution of these modifiable factors. 
 
8 
 
Previous studies have consistently shown that CKD is associated with increased body mass index (BMI) 
[61,62]. This is because overweight and obese people are also likely to have poor glycemic control, 
uncontrolled hypertension and other cardiovascular cormobidities which can contribute to CKD 
progression. It should be noted however that body mass index was not found to be associated to CKD in 
our study. This will also be explored further.  
 
CKD has been found to be independently associated with HIV positive status, and this is due to a number 
of factors. These may include the fact that HIV positive patients live longer; consequently, get exposed to 
other traditional risk factors for CKD, effect of co-infections like Hepatitis B, CD4 less than 200/mm3 , high 
viral loads and the side-effects of some antiretroviral medications [63, 64]. We expected that HIV positive 
status on top of DM in our study participants may play an additive role making this subgroup more at risk 
of CKD; however, there was no association between HIV status and CKD in our study. Possible reasons 
for a lack of association include a small sample size of HIV positive patients in this study (n=38). On the 
other hand, while a previous case matched study in Botswana [65] showed HIV positive status to be 
associated with CKD, which was significant for those with lower CD4 less than 200umol/l, in the current 
study HIV positive patients had higher CD4 levels (mean of 641.58umol/l) [8] and this could explain the 
difference. In addition, HIV status did not impact on adherence rates in patients with DM, perhaps 
because they were followed up more [8]. We have seen this situation in other African countries [58].   
 
Understanding of the estimated glomerular filtration rate for individual patients helps in renal adjustment 
dosages of medications including oral hypoglycemic agents (OHA) to avoid complications such as 
hypoglycemia and lactic acidosis [40].  Our study showed that patients were more significantly prescribed 
insulin as estimated GFR declined, making them at least less likely to suffer complications of OHAs. It 
should be noted that, out of 8.4% with CKD, only 4.9% of them had diagnosis of kidney disease 
documented in their charts. These patients with undocumented CKD disease are potentially at high risk of 
toxicities of several medications due to lack of renal dosage adjustment. 
 
There is growing evidence that heat stress coupled with inadequate hydration is associated with CKD that 
is different from that caused by traditional risk factors [66-68]. We did not study the role of heat stress on 
CKD among DM patients; however it should be noted that this study involved using serum creatinine 
results that were within 6 months of study duration (January to September 2015) with temperatures 
averaging between 250 C in January and 210 C in September. Botswana experiences a winter season 
between May to end of August, where mean temperature ranges from 13-16 0 C [69]. There is a need for 
future prospective studies involving different seasons of the year to elicit the role of heat stress on CKD 
among the DM population, and this will be the subject of future research in Botswana. 
 
The findings of this study provide data for the prevalence and associated factors for CKD in Botswana, 
providing a baseline for future local studies to enhance our understanding and better management of DM 
patients with CKD. However, the results of this study need to be interpreted with some limitations to put 
the findings into perspective. Firstly, this study being an observational cross-sectional design does not 
provide information on causal relationships and possible factors such as cardiovascular events that might 
have caused a rapid deterioration of renal function. Secondly, the use of a single serum creatinine results 
to calculate estimated glomerular filtration rates instead of at least two serum levels performed three 
months apart is another limitation. We also recruited ambulatory patients in our outpatient clinic who had 
no acute illnesses that may have predisposed them to acute kidney injuries; consequently, we believe 
that singe serum creatinine used here represent the stable state of our patients. Thirdly, we used 
estimated GFR by MDRD equation; this has not been validated against gold standard GFR in Botswana. 
Despite these limitations, we believe that this study provides insights into several key areas which call for 
future research and changes in management in Botswana. 
 
5. CONCLUSIONS 
 
The prevalence of CKD by estimated eGFR was low compared to most previous studies. However, half of 
patients with CKD are not documented resulting in potential of prescription errors and drug toxicity. A 
substantial number of our patients had uncontrolled hypertension and poor glycemic control. Older age, 
low level of education and longer duration of DM were associated with CKD. There is a need to carry out 
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prospective studies to determine the association and role of glycemic and blood pressure control in CKD 
causation among patients with DM in Botswana.  
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